Novel metabolic targeted LC-MS/MS assay to differentiate pancreatic cancer from chronic pancreatitis in plasma
Objectives Pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor prognosis with overall 5-year survival rates of less than 6%. In resectable pancreatic cancer cases, the 5-year survival rates increase to 18-24%. Therefore, an early diagnosis is key of a potentially curative treatment, and screening of patients at risk is desirable. Chronic pancreatitis (CP) patients have a 26-fold increased risk for the development of pancreatic cancer. Conventional diagnostic methods such as transabdominal ultrasound and CA19-9 testing suffer from insufficient clinical performance.
Source: Pancreatology - Category: Gastroenterology Authors: Julia Mayerle, Holger Kalthoff, Beate Kamlage, Gordian Adam, Nicole Christiansen, Philipp Schatz, Tim Fahlbusch, Bianca Bethan, Silke Schulze Pellengahr, Solveigh Krusekopf, Ansgar Chromik, Fritz Klein, Marcus Bahra, Marius Distler, Christian Pilarsky, Ro Tags: Session 5. Pancreatic Cancer: predispositions and diagnostic advances - free papers Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer | Pancreatitis | Ultrasound